Putting AUVI-Q to the test:
Helping patients understand how to use their AUVI-Q.
100% of adults and 95% of pediatric patients were able to complete a simulated injection with AUVI-Q on the first attempt in a design validation and labeling comprehension study, without committing a critical use error or receiving any training from a healthcare practitioner.13
were able to complete a simulated injection with AUVI-Q on the first attempt.13
Designed with size in mind.
About the size of a credit card and thickness of a cell phone, AUVI-Q fits in most pockets, small purses, and diaper bags.
The first and only epinephrine auto-injector with an auto-retractable needle.
The AUVI-Q auto-retractable needle is not visible before, during, or after injection, and completes epinephrine injection in seconds.†
†Epinephrine injection is complete in less than half a second. However, you must push firmly and hold for a complete 2-second count.
If you inject a young child or infant with AUVI-Q, hold their leg firmly in place before and during the injection to prevent injuries. Ask your healthcare provider to show you how to properly hold the leg of a young child or infant during an injection.7
AUVI-Q contains an electronic voice instruction system to help guide users through the entire epinephrine injection.7
A 2-second countdown begins after AUVI-Q is activated. Voice instructions will indicate the injection is complete, AUVI-Q will beep, and the lights will blink red. After use, seek immediate medical attention.7
AUVI-Q can inject through clothing, if necessary. ONLY inject into the middle of the outer thigh.
To minimize the risk of injection-related injury when administering AUVI-Q to young children or infants, remember to hold a child’s leg in place during an injection with AUVI-Q and limit movement prior to and during injection.
AUVI-Q® (epinephrine injection, USP) is a prescription medicine used to treat life-threatening allergic reactions, including anaphylaxis, in people who are at risk for or have a history of serious allergic reactions.
Important Safety Information
AUVI-Q is for immediate self (or caregiver) administration and does not take the place of emergency medical care. Seek immediate medical treatment after using AUVI-Q. Each AUVI-Q contains a single dose of epinephrine. AUVI-Q should only be injected into your outer thigh, through clothing if necessary. If you inject a young child or infant with AUVI-Q, hold their leg firmly in place before and during the injection to prevent injuries. Do not inject AUVI-Q into any other part of your body, such as into veins, buttocks, fingers, toes, hands, or feet. If this occurs, seek immediate medical treatment and make sure to inform the healthcare provider of the location of the accidental injection. Only a healthcare provider should give additional doses of epinephrine if more than two doses are necessary for a single allergic emergency.
Rarely, patients who use AUVI-Q may develop infections at the injection site within a few days of an injection. Some of these infections can be serious. Call your healthcare provider right away if you have any of the following symptoms at an injection site: redness that does not go away, swelling, tenderness, or the area feels warm to the touch.
If you have certain medical conditions, or take certain medicines, your condition may get worse or you may have more or longer lasting side effects when you use AUVI-Q. Be sure to tell your healthcare provider about all the medicines you take, especially medicines for asthma. Also tell your healthcare provider about all of your medical conditions, especially if you have asthma, a history of depression, thyroid problems, Parkinson’s disease, diabetes, heart problems or high blood pressure, have any other medical conditions, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Epinephrine should be used with caution if you have heart disease or are taking certain medicines that can cause heart-related (cardiac) symptoms.
Common side effects include fast, irregular or ‘pounding’ heartbeat, sweating, shakiness, headache, paleness, feelings of over excitement, nervousness, or anxiety, weakness, dizziness, nausea and vomiting, or breathing problems. These side effects usually go away quickly, especially if you rest. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
You are leaving www.auvi-q.com
By clicking OK, you will leave www.auvi-q.com and go to a third-party site that is not operated by AUVI-Q® (epinephrine injection, USP). We are not responsible for the content or availability of linked sites.
All patients with commercial insurance, including those with high-deductible plans, can get AUVI-Q® (epinephrine injection, USP) in 2 easy steps through the direct delivery service. To get started, simply download and fill out your information, then bring the form to your physician to complete.
Please see full terms and conditions.
Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107(1):191-193.
Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med. 1992;327(6):380-384.
Bock SA, Muñoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol. 2007;119(4):1016-1018.
Kim H, Fischer D. Anaphylaxis. Allergy Asthma Clin Immunol. 2011;7(Suppl 1):S6
Hochstadter E, Clarke A, De Schryver S, et al. Increasing visits for anaphylaxis and the benefits of early epinephrine administration: A 4-year study at a pediatric emergency department in Montreal, Canada. J Allergy Clin Immunol. 2016;137(6):1888-1890.
Edwards ES, Edwards ET, Gunn R, Patterson P, North R. Design validation and labeling comprehension study for a new epinephrine autoinjector. Ann Allergy Asthma Immunol. 2013;110(3):189-193.
Simons FER. Anaphylaxis in infants: can recognition and management be improved? J Allergy Clin Immunol. 2007;120(3):537-540.
Motosue M, Bellolio MF, Van Houten HK, Shah ND, Campbell RL. Increasing emergency department visits for anaphylaxis, 2005-2014. J Allergy Clin Immunol Pract. 2017;5(1):171-175.e1-3.
Rudders S, Banerji A, Clark S, Camargo CA Jr. Age-related differences in the clinical presentation of food-induced anaphylaxis. J Pediatr. 2011;158(2):326-328.
Terms and Conditions
Only valid for commercially insured patients in the 50 United States and DC through the direct delivery service. Not eligible if prescriptions are paid for in part/full by state or federally funded program(s), like Medicare Part D, Medicaid, Vet. Aff., Dept. of Def., or Tricare, and where prohibited by law. Offer is not insurance. Offer cannot be sold, purchased, traded, transferred, and cannot be combined with any other offer. Offer may change at any time, without notice. Call 1-877-30-AUVIQ for questions regarding eligibility.
The November 2017 update to the AUVI-Q (epinephrine injection, USP) label included a change in hold time from 5 seconds to 2 seconds. There has been no change in how the AUVI-Q device delivers epinephrine; the functionality of the device is the same. AUVI-Q has always delivered the epinephrine dose in less than 2 seconds. This change in the hold time from 5 seconds to 2 seconds is a labeling change to more accurately reflect the time it takes to deliver a complete epinephrine dose.
There is no need to return your current AUVI-Q or to get a new prescription.